

MERIT Announces Strategic Collaboration with MTI to Provide Spirometry Endpoints

For Too Long, Spirometry Had One Way In. Not Anymore.

MADISON, WI, UNITED STATES, May 13, 2026 /EINPresswire.com/ -- MERIT CRO, Inc. (MERIT) has partnered with Monitored Therapeutics, Inc. (MTI) to offer a new standard for spirometry endpoints—combining deep endpoint expertise with advanced respiratory measurement. This partnership gives sponsors a compelling, high-quality alternative in a space that’s overdue for innovation.



Under the collaboration, MTI provides respiratory data capture through its GoSpiro® platform and Lisa, a real-time avatar-assisted coaching system that guides participants through spirometry maneuvers to improve consistency and repeatability. MERIT brings the power of

human oversight, providing review by respiratory experts who ensure every effort meets rigorous scientific and clinical standards.

“

This partnership accelerates the future of respiratory assessment. Together, we’re setting a new benchmark for how spirometry should be captured, reviewed, and trusted.”

Heather Baumhauer, Chief Operating Officer of MERIT

Through EXCELSIOR™, MERIT’s secure, cloud-based platform, teams gain full visibility into all spirometry data (accepted and rejected efforts) with 24/7 real-time access for total transparency and operational efficiency. Together, MTI and MERIT create a fully integrated digital-plus-expert ecosystem that elevates data integrity, participant experience, and study confidence from end to end.

“This partnership accelerates the future of respiratory assessment,” said Heather Baumhauer, Chief Operating Officer of MERIT. “Uniting MERIT’s expert oversight with MTI’s Avatar-Assisted Technology will deliver data clarity and confidence at a scale the industry has never seen. Together, we’re setting a new benchmark for how spirometry should be captured, reviewed, and

trusted.”

“Partnering with MERIT expands what’s possible in respiratory data collection,” said Michael Taylor, Chief Clinical Officer and Co-Founder of MTI. “Together, we’re combining real-time patient guidance with centralized respiratory expertise and oversight to deliver more consistent, transparent, and reliable spirometry data for sponsors and CROs.”

About MERIT

MERIT is an innovative, global clinical and preclinical trial endpoint and technology services provider working in a variety of therapeutic areas, including ophthalmology, respiratory, oncology, and cardiology. We partner with pharmaceutical and biotech sponsors as well as CROs to deliver reliable endpoint services in multi-regional trials. Together, our work advances and accelerates the improvement of therapeutic options for patients worldwide. MERIT has offices in Madison, WI, Shanghai, China, Toronto, Canada, and Sydney, Australia. <https://meritcro.com/>

About MTI

MTI is a respiratory technology company focused on making high-quality lung function testing more accessible, more consistent, and easier to deliver across healthcare and clinical research. We connect devices, software, and guided workflows into a single platform that supports respiratory testing in clinic and at home—helping providers, health systems, pharmaceutical sponsors, and CROs expand access, reduce variability, and generate data they can trust. <https://monitoredrx.com/>

Stacy Sanderson

MERIT

+1 608-284-8810

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[YouTube](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/912345457>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.